DR. ROBERTA ALICE WEISS, M.D.
Osteopathic Medicine at Clover Hill Rd, Penn Wynne, PA
License number
Pennsylvania MD040115E
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Pennsylvania MD040115E
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
936 Clover Hill Rd, Penn Wynne, PA 19096
Phone
(610) 212-3474
Professional information
Dr. Roberta A Weiss - MD (Doctor of Medicine)
Hospitals:
936 Clover Hill Rd, Wynnewood 19096
936 Clover Hill Rd, Wynnewood 19096
936 Clover Hill Rd, Wynnewood 19096
Education:
Medical Schools
University Of Pennsylvania School Of Medicine
Graduated: 1986
University Of Pennsylvania School Of Medicine
Graduated: 1986
Methods Of Administering Anti-Tnfalpha Antibodies
US Patent:
2012017, Jul 12, 2012
Filed:
Nov 3, 2011
Appl. No.:
13/288299
Inventors:
Steven A. Fischkoff - Short Hills NJ, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US
Assignee:
ABBOTT BIOTECHNOLOGY LTD. - HAMILTON
International Classification:
A61K 39/395, A61P 1/00, A61P 1/04, A61K 38/20
US Classification:
424 852, 4241581, 4241351
Abstract:
Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
Methods Of Administering Anti-Tnfalpha Antibodies
US Patent:
2013000, Jan 3, 2013
Filed:
Jun 22, 2012
Appl. No.:
13/530363
Inventors:
Steven A. Fischkoff - Short Hills NJ, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US
Assignee:
Abbott Biotechnology Ltd. - Hamilton
International Classification:
A61K 39/395, A61P 37/06, A61P 31/00, A61P 37/00, A61P 35/00, A61P 29/00
US Classification:
4241581
Abstract:
Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
Methods Of Administering Anti-Tnfalpha Antibodies
US Patent:
2003023, Dec 25, 2003
Filed:
Jun 5, 2002
Appl. No.:
10/163657
Inventors:
Steven Fischkoff - Short Hills NJ, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US
International Classification:
A61K039/395
US Classification:
424/145100, 424/141100
Abstract:
Methods of treating disorders in which TFN activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF (e.g., K=10M or less), a slow off rate for hTNF dissociation (e.g., K=10secor less) and neutralize hTNF activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.